Judge Roopwant K, Henry Peter J, Mirtschin Peter, Jelinek George, Wilce Jacqueline A
Molecular Genetics and Evolution Group, Research School of Biological Sciences, Australian National University, Canberra 2601, ACT, Australia.
Toxicol Appl Pharmacol. 2006 Jun 1;213(2):117-25. doi: 10.1016/j.taap.2005.09.010. Epub 2005 Oct 26.
The Australian snakes of the genus Pseudonaja (dugite, gwardar and common brown) account for the majority of snake bite related deaths in Australia. Without antivenom treatment, the risk of mortality is significant. There is an accumulating body of evidence to suggest that the efficacy of the antivenom is limited. The current study investigates the protein constituents recognized by the antivenom using 2-DE, immuno-blot techniques and rat tracheal organ bath assays. The 2-DE profiles for all three snake venoms were similar, with major species visualized at 78-132 kDa, 32-45 kDa and 6-15 kDa. Proteins characterized by LC-MS/MS revealed a coagulant toxin ( approximately 42 kDa) and coagulant peptide ( approximately 6 kDa), as well as two PLA(2) ( approximately 14 kDa). Peptides isolated from approximately 78 kDa and 15-32 kDa protein components showed no similarity to known protein sequences. Protein recognition by the antivenom occurred predominantly for the higher molecular weight components with little recognition of 6-32 kDa MW species. The ability of antivenom to neutralize venom activity was also investigated using rat tracheal organ bath assays. The venoms of Pseudonaja affinis affinis and Pseudonaja nuchalis incited a sustained, significant contraction of the trachea. These contractions were attributed to PLA(2) enzymatic activity as pre-treatment with the PLA(2) inhibitor 4-BPB attenuated the venom-induced contractions. The venom of Pseudonaja textilis incited tracheal contractility through a non-PLA(2) enzymatic activity. Neither activity was attenuated by the antivenom treatment. These results represent the first proteomic investigation of the venoms from the snakes of the genus Pseudonaja, revealing a possible limitation of the brown snake antivenom in binding to the low MW protein components.
澳大拉西亚拟眼镜蛇属(虎蛇、西部拟眼镜蛇和东部拟眼镜蛇)的蛇类导致了澳大利亚大部分与蛇咬伤相关的死亡。若不进行抗蛇毒血清治疗,死亡风险很高。越来越多的证据表明抗蛇毒血清的疗效有限。本研究采用二维电泳(2-DE)、免疫印迹技术和大鼠气管器官浴实验,研究了抗蛇毒血清识别的蛋白质成分。三种蛇毒的二维电泳图谱相似,主要蛋白条带出现在78 - 132 kDa、32 - 45 kDa和6 - 15 kDa处。通过液相色谱-串联质谱(LC-MS/MS)鉴定的蛋白质包括一种凝血毒素(约42 kDa)、一种凝血肽(约6 kDa)以及两种磷脂酶A2(约14 kDa)。从约78 kDa和15 - 32 kDa蛋白质组分中分离出的肽段与已知蛋白质序列无相似性。抗蛇毒血清主要识别较高分子量的组分,对6 - 32 kDa分子量的组分识别较少。还利用大鼠气管器官浴实验研究了抗蛇毒血清中和毒液活性的能力。虎蛇和纽氏拟眼镜蛇的毒液可引起气管持续、显著的收缩。这些收缩归因于磷脂酶A2的酶活性,因为用磷脂酶A2抑制剂4-溴苯甲酰苯酯预处理可减弱毒液诱导的收缩。东部拟眼镜蛇的毒液通过非磷脂酶A2酶活性引起气管收缩。两种活性均未因抗蛇毒血清治疗而减弱。这些结果代表了对拟眼镜蛇属蛇类毒液的首次蛋白质组学研究,揭示了棕蛇抗蛇毒血清在结合低分子量蛋白质组分方面可能存在的局限性。